BioAge Shifts Focus to Eye Disease After ZEUS Trial Results

BioAge Labs is reorienting its clinical strategy toward ophthalmic indications, specifically targeting diabetic macular edema (DME) with its lead candidate, BGE-102. The pivot follows cooling interest in the cardiovascular inflammation sector after the failure of Novo Nordisk's ZEUS trial, which served as a benchmark for similar therapeutic approaches.

"This is a unique feature of our molecule, too, which is that as an oral agent, it penetrates the eye really well. The blood-brain barrier and the blood-retina barrier are not dissimilar," said Kristen Fortney, CEO of BioAge, during the Citi Biopharma Summit.

Clinical Progress and BGE-102

The company has initiated a Phase II efficacy trial for BGE-102 to capitalize on the molecule's ability to cross the blood-retina barrier. BioAge expects to report top-line data from this study in the second half of 2026.

This shift is a departure from the inflammation-focused cardiovascular models that have faced increased scrutiny from investors. By applying their platform to DME, BioAge aims to address a market with established regulatory pathways. The company is also leveraging the oral administration profile of BGE-102, which differs from the anti-VEGF injections that currently dominate the treatment market.

Financial Position and Market Performance

BioAge reports sufficient liquidity as it enters this new phase of development. According to company disclosures, BioAge held $381 million in cash as of the end of Q2 2025. This balance is expected to fund operations through 2029, providing a runway for the company to reach clinical milestones without the immediate need for additional capital raises.

In public markets, BioAge (BIOA) shares were trading at $8.39 as of September 11, 2026.

Strategic Implications

The pivot highlights the challenges biopharma firms face when high-profile trials in related therapeutic areas underperform. The failure of the ZEUS trial, which investigated anti-inflammatory treatments for cardiovascular health, forced a re-evaluation of market expectations for similar mechanisms. By refocusing on eye disease, BioAge is positioning its pipeline in a space where oral systemic treatments are sought as alternatives to invasive ocular therapies.